MetaBiom
Microbiome & Chronic Diseases

Evidence Based Medicine
Sign in

Disease ⇒ Celiac Disease {40000207}

Record Keys


Type:
Disease
Parent:[  ]
Definition:
Celiac Disease

Details


Initialisation date:[  ]
Other Terms:
CD, Coaliac disease

Links


Meta Information


MedDra ID:
10009839
MedDra Level:
pt
ICD:[  ]
Category:
Gastroenterology, Immunology
Zone:[  ]
Mechanism:[  ]

Notes:


- Inflammation in celiac disease primarily occurs in the upper small intestine known as the duodenum, and microbial changes that occur in feces may not reflect the changes that occur in the small intestine.

References Notes


[  ]

Shared Reference Notes


  • [1.21
    - H. pylori has a mild protective role against celiac disease. Although this negative association is not strong.
  • [1.16
    - increase in Actinobacteria species in the upper tract (pharynx and duodenum), and an increase in Proteobacteria in the lower tract (duodenum and stool). - The effect of adherence to a gluten-free diet (GFD) evidenced by an increase in beneficial bacteria and a decrease in some Betaproteobacteriales but not fully restoring CeD-related dysbiosis. - gut microbiota acts as an enhancer of immune response in CeD through the production of lipopolysaccharides and other bacterial components that activate the immune response and by decrease SCFA producers bacteria.
  • [1.24] [#Nonceliac gluten sensitivity] [#Gluten-free diet (GFD)
    - Pre-existing fecal microbiome diversity was unaffected by gluten challenge in adult subjects with CD and NCGS. These findings suggest that current microbiome status is unrelated to current disease activity and disease severity.
  • [1.25] [#Obesity
  • [1.10
    - Microbiota composition and predicted function in Celiac Disease was largely determined by intestinal location. In the duodenum, but not stool, there was higher abundance of #Escherichia coli, #prevotella salivae, and #Neisseria. - #Neisseria, an opportunistic pathogen previously found to be increased in patients with active celiac disease, was associated with more severe enteropathy. - Expression of microbial glutamate carboxypeptidase was lower in the duodenum of celiac patients, and its decrease in mice also correlated with impaired gluten degradation, suggesting a potential candidate for future therapeutic development.
  • [1.27] [#Migraine] [#CGRP, #Glutamate, #Serotonin (5-hydroxytryptamine)
  • [1.9] [#Clostridium cluster XIVa] [#Taurodeoxycholic acid (TDCA)
    - 26 plasma metabolites, five cytokines, and one chemokine were significantly altered in CD progressors at age 5. - CD > 2-fold increase in TDCA. - TDCA feeding alone stimulates an inflammatory immune response in the small intestines of C57BJ/6 mice and causes villous atrophy, the hallmark of CD. - TDCA, a microbiota-derived metabolite, enriched in CD progressors’ plasma, has the potential to drive inflammation in the small intestines and enhance CD pathogenesis. - TDCA, is a conjugated bile acid that is mainly produced by gut microbes, particularly Clostridium XIVa and Clostridium XI, with 7-α-dehydroxylation of taurocholic acid and cholic acid. - TDCA was previously shown to be a proinflammatory metabolite. - several Clostridium XIVa ASVs were significantly more abundant in CD samples, especially at age 5. - Clostridium XIVa ASVs were highly targeted by IgA in CD progressors.
  • [1.19
    - Bacteroides vulgatus is increased in Infants with the genotype of high risk of celiac disease development. - Increased Bacteroides fragilis increase the risk for celiac disease development in genetically predisposed infants who were formula-fed. - Polysaccharide A produced by Bacteroides fragilis direct the immune system via its ability to direct the development of CD4+ T cells, thus inducing the differentiation of Th1-lineage. - Increased abundance of Bacteroides may contribute to the Th1 response found in the small intestinal mucosa of celiac disease patients.

Common References